From the author's experience, most pharmaceutical and biotechnology companies came to India for cost savings. All of them
stayed for India's quality in scientific talent and infrastructure. And today, most of them are investing in the country for
growth and productivity. Some Indian executives have the necessary wherewithal, will, stamina, and long-term commitment to
serve the industry and to create value for all involved. As the life sciences industry metamorphoses into its next phase,
executives at global biotechnology and pharmaceutical companies need to think of India in a more open-minded, comprehensive,
and collaborative manner to fully exploit its potential.
Nailesh A. Bhatt is managing director at Proximare Inc., 100 Overlook Center, Princeton, NJ 08540, tel. 732. 297.7007, email@example.com
1. Global Business Policy Council, "FDI Confidence Index," (A.T. Kearney, Alexandria, VA, 2005).